Seattle Genetics and Astellas have filed their antibody-drug conjugate enfortumab vedotin with the US drug regulator for advanced bladder cancer, after failure of chemotherapy and immunothe
Roche and Merck & Co have got their respective immunotherapies Tecentriq and Keytruda approved in bladder cancer – but the problem of low response rates remains. At the ASCO an
Johnson & Johnson’s Balversa has become the first targeted therapy for bladder cancer after an FDA approval at the tail end of last week for patients with mutations in the FGFR gene.
Bristol-Myers Squibb has broadened a collaboration with Infinity Pharmaceuticals as it seeks to find combinations that boost the potency of its cancer immunotherapy, Opdivo.
